Broderick Brian C Has $617,000 Holdings in Bristol Myers Squibb Company (NYSE:BMY)

Broderick Brian C trimmed its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 14.4% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 10,117 shares of the biopharmaceutical company’s stock after selling 1,700 shares during the quarter. Broderick Brian C’s holdings in Bristol Myers Squibb were worth $617,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Pinney & Scofield Inc. bought a new stake in shares of Bristol Myers Squibb in the fourth quarter valued at approximately $25,000. Park Square Financial Group LLC acquired a new position in Bristol Myers Squibb in the 4th quarter valued at $26,000. Fairway Wealth LLC bought a new stake in shares of Bristol Myers Squibb during the 4th quarter valued at $28,000. Transce3nd LLC acquired a new stake in shares of Bristol Myers Squibb during the 4th quarter worth $28,000. Finally, Global Wealth Strategies & Associates increased its position in shares of Bristol Myers Squibb by 137.5% in the first quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 275 shares during the period. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol Myers Squibb Stock Performance

Shares of BMY stock opened at $47.25 on Wednesday. The firm has a market capitalization of $96.15 billion, a price-to-earnings ratio of 17.70, a PEG ratio of 1.42 and a beta of 0.38. The company has a current ratio of 1.28, a quick ratio of 1.17 and a debt-to-equity ratio of 2.65. The business’s 50-day moving average price is $48.49 and its 200-day moving average price is $54.58. Bristol Myers Squibb Company has a 12 month low of $39.35 and a 12 month high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, topping the consensus estimate of $1.50 by $0.30. Bristol Myers Squibb had a net margin of 11.38% and a return on equity of 87.62%. The business had revenue of $11.20 billion for the quarter, compared to the consensus estimate of $10.77 billion. During the same period last year, the company earned ($4.40) EPS. The firm’s revenue was down 5.6% compared to the same quarter last year. Equities research analysts forecast that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, August 1st. Investors of record on Thursday, July 3rd will be given a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a yield of 5.25%. Bristol Myers Squibb’s dividend payout ratio is currently 92.88%.

Insiders Place Their Bets

In other news, EVP Samit Hirawat bought 4,250 shares of the firm’s stock in a transaction on Friday, April 25th. The stock was acquired at an average price of $47.58 per share, with a total value of $202,215.00. Following the transaction, the executive vice president now owns 83,513 shares of the company’s stock, valued at $3,973,548.54. This trade represents a 5.36% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.07% of the company’s stock.

Analyst Ratings Changes

BMY has been the subject of several recent analyst reports. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $55.00 price objective (down previously from $67.00) on shares of Bristol Myers Squibb in a research report on Tuesday, April 8th. UBS Group cut their price target on shares of Bristol Myers Squibb from $60.00 to $54.00 and set a “neutral” rating for the company in a report on Friday, April 11th. Cantor Fitzgerald reissued a “neutral” rating and issued a $55.00 price objective on shares of Bristol Myers Squibb in a research note on Tuesday, April 22nd. Argus upgraded shares of Bristol Myers Squibb to a “hold” rating in a research report on Friday, April 25th. Finally, Wall Street Zen downgraded Bristol Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Friday, June 6th. Two equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, six have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $58.00.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.